VistaGen Therapeutics Depreciation & Amortization 2011-2026 | VTGN

Annual Depreciation & Amortization VistaGen Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
150 K	127 K	130 K	154 K	118 K	103 K	91.2 K	80.7 K	54.9 K	53.5 K	59.1 K	54.6 K	33.8 K	45.6 K	45.3 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
154 K	33.8 K	86.7 K

Quarterly Depreciation & Amortization VistaGen Therapeutics

2025-Q4	2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	40 K	-	-	34 K	-	-	32 K	-	30.6 K	96.2 K	32.3 K	-	43.7 K	115 K	71.2 K	-	26.4 K	25.5 K	25.4 K	-	25.5 K	77.6 K	52.1 K	26.2 K	-	64.8 K	37.9 K	-	-	-	23.6 K	-	-	37.6 K	26 K	-	-	40.8 K	28.9 K	-	-	39.2 K	26.2 K	-	-	40.2 K	25.8 K	-	-	21 K	11.8 K	-	-	33.5 K	21.3 K	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
115 K	11.8 K	39.7 K

Depreciation & Amortization of other stocks in the Biotechnology industry

Issuer	Depreciation & Amortization	Price	% 24h	Market Cap	Country
Acorda Therapeutics ACOR	31.7 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	3.65 M	-	-	$ 86.2 M	USA
Akouos AKUS	2.49 M	-	0.23 %	$ 488 M	USA
Alnylam Pharmaceuticals ALNY	55.7 M	$ 322.18	-3.36 %	$ 42.2 B	USA
Applied Molecular Transport AMTI	3.13 M	-	-	$ 10.1 M	USA
I-Mab IMAB	23.9 M	-	-	$ 866 M	China
AlloVir ALVR	13 K	-	4.14 %	$ 49.1 M	USA
Cabaletta Bio CABA	1.65 M	$ 3.51	3.09 %	$ 353 M	USA
Aligos Therapeutics ALGS	930 K	$ 7.72	4.04 %	$ 76.3 M	USA
Allakos ALLK	6.14 M	-	-	$ 28.6 M	USA
Ayala Pharmaceuticals AYLA	162 K	-	-	$ 7.46 M	Israel
Aptinyx APTX	122 K	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	886 K	-	-13.39 %	$ 1.45 M	USA
Brainstorm Cell Therapeutics BCLI	199 K	-	-2.5 %	$ 5.88 M	USA
Amphastar Pharmaceuticals AMPH	31.6 M	$ 22.0	1.48 %	$ 1.03 B	USA
CymaBay Therapeutics CBAY	681 K	-	-	$ 3.45 B	USA
Advaxis ADXS	369 K	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	58 K	-	5.93 %	$ 314 M	Canada
Can-Fite BioPharma Ltd. CANF	24 K	$ 3.07	-3.15 %	$ 5.05 M	Israel
AgeX Therapeutics AGE	100 K	-	-10.17 %	$ 12.2 K	USA
Galectin Therapeutics GALT	1 K	$ 2.25	-12.11 %	$ 144 M	USA
ContraFect Corporation CFRX	154 K	-	-5.16 %	$ 5.39 M	USA
Aeglea BioTherapeutics AGLE	744 K	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	1.27 M	$ 1.38	-10.97 %	$ 355 M	USA
Applied Genetic Technologies Corporation AGTC	1.51 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	548 K	$ 4.28	0.94 %	$ 458 M	USA
Arcutis Biotherapeutics ARQT	700 K	$ 23.69	-3.64 %	$ 3.01 B	USA
AIkido Pharma AIKI	105 K	-	1.93 %	$ 17.4 M	USA
BioDelivery Sciences International BDSI	140 K	-	-4.8 %	$ 255 M	USA
Autolus Therapeutics plc AUTL	8.3 M	$ 1.59	6.71 %	$ 423 M	Britain
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
BeiGene, Ltd. BGNE	142 M	-	0.49 %	$ 251 B	Cayman-islands
Caladrius Biosciences CLBS	174 K	-	-16.75 %	$ 25.8 M	USA
AVROBIO AVRO	617 K	-	1083.1 %	$ 745 M	USA
Clearside Biomedical CLSD	67 K	-	-	$ 25.3 M	USA
Celldex Therapeutics CLDX	3.38 M	$ 33.63	-0.72 %	$ 2.23 B	USA